Instalab
logoInstalab

Alternative Complement Pathway Activity

Blood Test
Investigate a possible gap in your defenses against serious bacterial infections.
4.8 (4,678 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Alternative Complement Pathway Activity test?

This test is most useful if any of these apply to you.

Getting Serious Bacterial Infections
This test can help investigate a complement deficiency after recurrent or unusually severe bacterial infections.
Being Evaluated for Complement-Related Kidney Disease
Activity adds context to a kidney workup, though a normal result cannot exclude complement-related disease.
Concerned About a Family History
A relative with a confirmed complement deficiency may make targeted testing useful for you.
Taking a Complement-Blocking Drug
Testing can help document pathway suppression when interpreted with your medicine, dose timing, and disease markers.

About Alternative Complement Pathway Activity

Repeated serious bacterial infections can be a reason to investigate complement function. So can certain kidney disorders in which complement damages your own tissues. This test helps assess whether the alternative pathway can complete its response, but interpreting it requires the infection history, medications, and other laboratory findings.

Alternative pathway activity is an established test for investigating complement deficiencies and assessing complement blockade during treatment. Its use as a general measure of immune fitness, future disease risk, or healthy aging remains unproven.

What This Test Measures

Complement is a group of immune proteins that helps coat germs for removal, attracts immune cells, and forms holes in susceptible cell membranes. It can start through three pathways: classical, lectin, and alternative. The alternative pathway maintains low-level background activity through spontaneous chemical changes in C3. Regulatory proteins normally keep that activity under control.

The alternative pathway also amplifies responses started through the other two pathways. In laboratory experiments using human serum, blocking factor D reduced more than 80% of certain final complement products after classical-pathway activation. That percentage describes those experimental conditions; the contribution varies with the target and the strength of the initial response.

This test uses serum obtained from a blood draw. Serum is the liquid remaining after blood clots. The functional plate-based assay activates the alternative pathway and measures formation of the final C5b-9 attack complex through a color reaction. This method is called ELISA, and activity is reported relative to a reference serum sample.

The result depends on the alternative pathway's own proteins and the shared proteins needed to finish the response. A low result can reflect a missing or poorly functioning protein, consumption during illness, a complement-blocking medicine, or deterioration of the sample. It does not identify the cause by itself.

Inherited Gaps in Infection Defense

Deficiencies of alternative or terminal complement proteins can increase susceptibility to serious bacterial infections, particularly infections caused by Neisseria bacteria. These include meningococcal meningitis and bloodstream infection. Some affected people first come to attention after a single severe infection.

Absent or markedly reduced alternative pathway activity with preserved CH50 suggests a defect in the alternative pathway. CH50 assesses the classical pathway and the shared terminal components. When both tests show reduced activity, the problem may involve a shared component such as C3 or C5 through C9, a regulatory protein, or widespread complement consumption.

Inheritance depends on the protein involved. Many complement deficiencies require a disease-causing variant inherited from each parent. Properdin deficiency follows an X-linked pattern and mainly affects males. Functional testing helps identify which part of the system needs closer investigation.

A routine activity result cannot settle whether an uncertain genetic variant causes disease. Specialized experiments can sometimes help. One published report used a modified cell-based assay to investigate factor B variants; that was a different method from this serum activity test.

Kidney Disease and Small-Vessel Injury

Poorly controlled complement can damage the lining of small blood vessels, promote tiny clots, destroy red blood cells, and injure the kidneys. This is the process involved in complement-mediated atypical hemolytic uremic syndrome, usually called aHUS. Some cases involve inherited changes in complement proteins or antibodies against factor H, but an identifiable genetic or antibody cause is not found in every case.

C3 glomerulopathy involves abnormal C3 deposits in the kidney's filters and often involves alternative pathway dysregulation. Blood complement findings help characterize the disease, while diagnosis depends on kidney biopsy findings. Normal blood activity can coexist with harmful complement activity on tissue surfaces.

A frequently cited diagnostic study included 147 people undergoing complement testing, but only 44 were being evaluated for small-vessel clotting disorders, and only eight had aHUS. All eight had an abnormality somewhere in a nine-test complement panel. A combination involving factor B and CH50 identified six of those eight cases and was negative in about 89% of the other clotting cases. Those findings concern a small, selected group and a combination of tests. They do not establish a normal AH50 or complement panel as a reliable way to exclude aHUS.

Other kidney studies need similar care. A case-control study found higher serum alternative pathway activity in people who already had hypertension-related kidney damage. Because the groups were compared at one point in time, it did not show that a higher result predicts future kidney decline.

In IgA nephropathy, deposits containing IgA antibodies injure the kidney's filters. One study found that higher plasma Ba was associated with more urine protein and worse kidney function. Ba is a fragment released when factor B is activated. Measuring that fragment in plasma is different from measuring the functional capacity of the pathway in serum.

What Studies in Critical Illness Show

In 321 critically ill adults, alternative pathway activity at or above the study median was associated with about half the odds of death within 30 days. Higher activity was also associated with better one-year survival and fewer bloodstream infections after adjustment for several clinical factors. Their serum controlled a drug-resistant bacterium more effectively in laboratory experiments.

That study used a rabbit-red-cell hemolytic assay. It measures related serum function through cell destruction, whereas this test uses formation of the attack complex on a plate. Its numerical results cannot be transferred directly to this assay.

A later analysis combined the subgroup with acute respiratory distress syndrome from that cohort with another serum cohort. Higher hemolytic activity was associated with roughly a third lower mortality during follow-up, which differed between cohorts. Separate measurements of factor B in serum or plasma across three cohorts linked relatively low concentrations with about twice the mortality. Protein concentration and functional activity are related but distinct measurements.

In a separate study of 154 adults hospitalized with COVID-19, serum activity measured with a plate-based assay was lower among those who died or needed invasive ventilation. Their median activity was about a quarter lower than in those without either outcome. These observations do not establish that raising activity improves survival or that testing healthy people before illness improves care.

Functional Capacity and Ongoing Activation

The amount of complement activity remaining in a serum sample differs from the amount of activation happening inside your body. Heavy activation can consume proteins and leave less functional capacity for the test to detect. That is one explanation for low activity during severe illness, but a low result alone does not prove consumption.

Activation products such as Ba, Bb, and soluble C5b-9 provide different information. They reflect products generated during complement activation, usually assessed in carefully handled plasma. Their concentrations also depend on clearance and sample handling, and soluble C5b-9 can be generated through any complement pathway. High activation products and low functional activity can occur together, but they are not interchangeable findings.

Heart and Blood Vessel Studies

The cardiovascular studies below measured individual complement proteins in serum or plasma. They provide context about complement biology, but none measured the functional activity reported by this test.

Who Was StudiedWhat Was MeasuredWhat Was Found
530 adults across two cohorts with advanced carotid artery diseasePlasma properdin below versus above the cohort medianLower properdin was associated with about 2.3 to 2.8 times the rate of cardiovascular death during roughly seven to eight years of follow-up.
A validation cohort of 436 adults with severe aortic valve narrowingPlasma factor B and its activation fragment BbHigher concentrations were associated with mortality after adjustment for other clinical factors.
370 adults undergoing coronary angiographySerum factor D, also called adipsinThe study's higher-concentration group had about four times the mortality during roughly six years of follow-up.

The findings vary by population and measurement. In 343 people with heart failure, plasma factor B and an alternative-pathway enzyme complex were increased but were not associated with mortality over about four years. In the Maastricht Study, associations between plasma factor D and arterial stiffness were no longer statistically clear in the full population after adjustment for metabolic risk factors. Another analysis found a modest association with existing cardiovascular disease.

These studies do not establish serum alternative pathway activity as a cardiovascular screening test or a target for heart-disease prevention.

Age, Sex, and Genetic Background

In a study of 120 healthy adults, serum activity measured with a plate-based assay tended to be higher at older ages and lower in women. Women also had lower concentrations of several complement proteins. These were comparisons between people, so they do not establish how your result should change as you age.

A study of 4,990 people identified genetic variants associated with functional activity across the three complement pathways. The identified variants explained about a sixth of the estimated inherited contribution to alternative pathway activity. The much larger figure sometimes quoted from this study concerned the lectin pathway.

Genetic background influences this result, but the activity itself can change with disease and treatment. These studies have not established an optimal activity level for healthy aging or shown that routine tracking improves health.

When Results Can Be Misleading

Complement proteins can lose function or become activated after collection. A low reading can therefore arise from what happened in the tube.

  • Sample handling: delayed separation, warm storage, and repeated freezing and thawing can reduce measured function. Cooling slows unwanted reactions but does not preserve a sample indefinitely.
  • Specimen choice: this functional assay uses serum. EDTA plasma is used for many activation-fragment tests, but EDTA blocks complement reactions and is unsuitable for this serum activity assay.
  • Illness and surgery: infection, inflammation, and recent surgery can change functional activity. These may be real temporary biological changes rather than evidence of an inherited deficiency.
  • Complement inhibitors: medicines that block factor B, C3, or C5 can suppress the result intentionally. Suppression must be interpreted in the context of the treatment and the time since the last dose.
  • Plasma exchange or plasma infusion: these procedures can change circulating complement proteins and complicate interpretation of your untreated activity.
  • Assay limitations: the plate-based test measures the ability to form a final attack complex under laboratory conditions. It can miss defects in how complement is controlled on your own cell surfaces, and results from different assay methods or laboratories are not directly interchangeable.
  • Kidney disease: reduced kidney function can affect concentrations of some complement proteins and fragments, especially factor D and Ba. That does not establish a predictable increase in this functional activity result.

What Moves This Biomarker

Evidence-backed interventions that affect your Alternative Complement Pathway Activity level

↓ Decrease
Iptacopan treatment
Iptacopan blocks factor B and strongly suppresses serum alternative pathway activity. This is beneficial when treating an appropriate complement-driven disease. In a randomized phase 2 IgA nephropathy trial, the highest studied dose produced sustained suppression on a plate-based functional assay and about 23% less urine protein than placebo after three months. A later phase 3 trial showed slower kidney-function decline over two years. Treatment increases susceptibility to serious infections.
MedicationStrong Evidence
↓ Decrease
Eculizumab or ravulizumab treatment
These medicines block C5 and strongly reduce the final complement response measured by this assay. This blockade can prevent tissue injury in conditions such as aHUS and is an intended treatment effect. A suppressed result does not by itself prove that disease is controlled. Both medicines substantially increase the risk of meningococcal infection despite vaccination.
MedicationStrong Evidence

Frequently Asked Questions

References

31 studies
  1. Mayo Clinic LaboratoriesMayo Clinic Laboratories
  2. ARUP LaboratoriesARUP Laboratories Test Directory
  3. J. S. Orange, Practice Parameter WorkgroupAnnals of Allergy, Asthma & Immunology2026
  4. M. Harboe, G. Ulvund, L. Vien, M. Fung, T. E. MollnesClinical & Experimental Immunology2004

Alternative Complement Pathway Activity Test

$239
FSA/HSA eligible
No Rx needed
HIPAA compliant